Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison Barraclough

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Blood Advances|July 10, 2019
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyAllison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Haematologica|February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma AllianceAllison Barraclough, James T England, Diego Villa, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.
Blood Advances|April 14, 2026
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesJamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Blood Advances|July 10, 2019
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyAllison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Haematologica|February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma AllianceAllison Barraclough, James T England, Diego Villa, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.
Blood Advances|April 14, 2026
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesJamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, et al.
Pageof 3